NCT07174336 2026-03-06
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
Clinical Trials
14 trialsNCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT06086340 2025-11-18
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
Pfizer
Completed
NCT04711252 2025-10-14
SERENA-4
AstraZeneca
Phase 3 Active not recruiting
NCT04158362 2025-09-22
AMBRE
UNICANCER
Phase 3 Active not recruiting
NCT07163481 2025-09-16
SoGreat
Hunan Cancer Hospital
Phase 1 Not yet recruiting
NCT02188745 2024-07-17
POLLY
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT02894398 2023-03-13
INGE-B
iOMEDICO AG
Phase 2 Completed
NCT02753686 2023-02-15
Treat ER+ight
Novartis
Completed
NCT03220178 2022-01-06
PRECYCLE
Palleos Healthcare GmbH
Phase 4 Terminated
NCT01197170 2021-01-22
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
Phase 1 Completed
NCT04666805 2020-12-14
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
First Hospital of China Medical University
Unknown
NCT00684216 2017-09-14
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
The Netherlands Cancer Institute
Phase 2/3 Terminated
NCT01151215 2014-07-25
MINT
AstraZeneca
Phase 2 Terminated